Search Results | OpenEmory

Start Over Keyword checkpoint inhibition therapy

Response to Abemaciclib and Immunotherapy Rechallenge with Nivolumab and Ipilimumab in a Heavily Pretreated TMB-H Metastatic Squamous Cell Lung Cancer with CDKN2A Mutation, PIK3CA Amplification and TPS 80%: A Case Report

Authors:Douglas Dias E Silva, Hospital Israelita Albert EinsteinGuilherme Bes Borba, Hospital Israelita Albert EinsteinJuliana R Beal, Hospital Israelita Albert EinsteinGehan Botrus, Emory UniversityAkemi Osawa, Hospital Israelita Albert EinsteinSérgio Eduardo Alonso Araujo, Hospital Israelita Albert EinsteinFernando Moura, Hospital Israelita Albert EinsteinRafael Aliosha Kaliks Guendelmann, Hospital Israelita Albert EinsteinPedro Luiz Serrano Uson Junior, Hospital Israelita Albert Einstein

Date:2023

Publisher:MDPI

Publication Version:Final Published Version

License:Creative Commons Attribution 4.0 International